Ironwood Pharmaceuticals (IRWD) Operating Leases (2019 - 2026)
Ironwood Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $9.9 million for Q4 2025.
- On a quarterly basis, Operating Leases fell 19.78% to $9.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.9 million, a 19.78% decrease, with the full-year FY2025 number at $9.9 million, down 19.78% from a year prior.
- Operating Leases hit $9.9 million in Q4 2025 for Ironwood Pharmaceuticals, down from $10.5 million in the prior quarter.
- Over the last five years, Operating Leases for IRWD hit a ceiling of $19.9 million in Q1 2021 and a floor of $9.9 million in Q4 2025.
- Historically, Operating Leases has averaged $15.2 million across 5 years, with a median of $15.3 million in 2023.
- Biggest five-year swings in Operating Leases: dropped 8.24% in 2021 and later decreased 19.78% in 2025.
- Tracing IRWD's Operating Leases over 5 years: stood at $18.5 million in 2021, then decreased by 10.2% to $16.6 million in 2022, then decreased by 12.39% to $14.5 million in 2023, then fell by 15.4% to $12.3 million in 2024, then dropped by 19.78% to $9.9 million in 2025.
- Business Quant data shows Operating Leases for IRWD at $9.9 million in Q4 2025, $10.5 million in Q3 2025, and $11.1 million in Q2 2025.